Post-induction MRD-driven treatment algorithm. Patients were divided into 3 separate groups: group A (MRD negative) received lenalidomide maintenance or no further treatment at the discretion of the investigator; group B (MRD positive, ASCT eligible) underwent ASCT; and group C (MRD positive, ASCT ineligible) received KRd consolidation for up to 12 cycles. Patients in group B could receive up to 12 cycles of KRd consolidation therapy if they remained MRD positive after ASCT. Conversion to MRD-negative status at any protocol specified time point allowed patients to receive lenalidomide maintenance or no further treatment at the investigator’s discretion.